Biotechnology

Syros Pharma

Rege Nephro Acquires Assets Related to Tamibarotene

Syros Pharma released FY2024 9 Months Earnings on October 31 Pre-Market (EST), with actual revenue of 0 USD and EPS of -0.8517 USD

Syros Pharmaceuticals released FY2024 Q3 earnings on October 31 Pre-Market (EST), actual revenue 0 USD (forecast 360 KUSD), actual EPS -0.1626 USD (forecast -0.676 USD)

Syros Pharma to Release FY2024 Q3 Earnings on October 31, Pre-Market EST; Forecasted Revenue 360K, EPS -0.676 USD

Investigation of Claims Against Syros Pharmaceuticals, Inc.

Investigation into Syros Pharmaceuticals, Inc.

EKSO Bionics

Profusa

Antelope Enterprise

Cemtrex

FLY-E

CID Holdco

Borealis Foods

Zhongchao

ON24

Aimei Health Tech

ADMA生物制药

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel制药

OpGen

福泰制药

再生元制药

阿里拉姆制药

Argenx

百济神州

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap